YD Bio (YDES) Receivables - Net (2024 - 2025)
YD Bio (YDES) posted quarterly Receivables - Net of $167.5 billion for Q4 2025, up 93.43% year-over-year from $86.6 billion in Q4 2024, and up 165115743.44% quarter-over-quarter from $101430.0 in Q2 2025.
YD Bio (YDES) Receivables - Net (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Receivables - Net for 2 consecutive years, with $167.5 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Net rose 93.43% year-over-year to $167.5 billion; the TTM figure through Dec 2025 stood at $167.5 billion (up 93.43% YoY), while the FY2025 annual figure was $167.5 billion, up 93.43% from the prior year.
- Receivables - Net climbed to $167.5 billion in Q4 2025 per YDES's latest filing, from $101430.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $167.5 billion in Q4 2025 and bottomed at $101430.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | YD Bio | 323.24 Mn | 317.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 167.48 Bn |
| Dec 31, 2025 | 167.48 Bn |
| Jun 30, 2025 | 101,430.00 |
| Jun 30, 2025 | 101,430.00 |
| Dec 31, 2024 | 86.58 Bn |
| Dec 31, 2024 | 86.58 Bn |